Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
Tuesday, March 10, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented promising preclinical data on PBGENE-DMD at the Muscular Dystrophy Association Clinical & Scientific Conference 2026. The findings indicate durable dystrophin expression and functional improvements in muscle pathology in a humanized DMD mouse model. This innovative gene editing approach aims to enhance muscle function through satellite cell editing.
Price reaction · baseline $4.71 (2026-03-09 close) · hit pre-market · 3 other DTIL headline(s) in the window, move may be shared
day 0 close
+13.6%
day 1
+7.4%
day 3 · peak
+20.4%
Market Sentiment Analysis
POSITIVE FACTORS
Durable dystrophin expression observed in preclinical studies.
Functional benefits noted in muscle improvement.
Innovative gene editing approach shows promise.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment in a humanized DMD mouse model demonstrates improvements in muscle pathology and biomarkers of muscle damage – – PBGENE-DMD
Frequently Asked Questions
What is PBGENE-DMD?
PBGENE-DMD is a gene editing treatment designed for muscular dystrophy.
What were the findings presented at the conference?
The findings showed durable dystrophin expression and functional muscle improvement.
What model was used for the PBGENE-DMD study?
A humanized DMD mouse model was used to demonstrate the treatment's effects.
What is the goal of the PBGENE-DMD approach?
The goal is to achieve durable functional muscle improvement through satellite cell editing.